PharmaTimes on 17. November 2015 The National Institute for Health and Care Excellence has published final draft guidance rejecting the use of Kadcyla (trastuzumab-emtansine) for patients as the first and only targeted chemotherapy for secondary HER2-positive breast cancer, because of its high price tag – around £90,000 per course (list price). Full article at PharmaTimes: […]
PharmaTimes on 18. Nov. 2015 Merck Serono’s Erbitux and Amgen’s Vectibix cannot be used as first line therapies alongside chemotherapy for RAS wild-type metastatic colorectal cancer. While recognising their clinical effectiveness, the Institute’s Expert Review group concluded that even if they were provided for free they would still not be cost-effective, as the methodology used […]
18. Nov. 2015 in PharmaTimes The National Institute for Health and Care Excellence has turned down Amgen’s Repatha – the world’s first approved PCSK9 inhibitor – as an option for people with high cholesterol and mixed dyslipidaemia. Key reasons for the negative decision were: (1) no long-term outcomes data and thus, the question of whether […]
Fierce Pharma, February 19, 2015 | By Eric Palmer Drugmakers are often at odds with the National Institute for Health and Care Excellence (NICE) in England, saying it is stingy in what it will approve as payments for their best new treatments. But the industry and the gatekeeper have pulled together in defending against a […]